PLEASANTON, Calif., Jan. 16, 2024 /PRNewswire/ -- Noctrix Health, Inc. announced today that it has closed a $40M Series C financing round led by Sectoral Asset Management with participation from other new investors Angelini Ventures, ResMed, and Asahi Kasei Corporation with strong support from insiders including OrbiMed and Treo Ventures.

加利福尼亚州普莱森顿（PLEASANTON，California），2024年1月16日/PRNewswire/-Noctrix Health，Inc.今天宣布，它已经完成了一轮4000万美元的C系列融资，由部门资产管理牵头，其他新投资者Angelini Ventures、ResMed和Asahi Kasei Corporation参与，并得到了包括OrbiMed和Treo Ventures在内的内部人士的大力支持。

This infusion of capital will propel the advancement of Nidra™ Tonic Motor Activation (TOMAC) therapy towards its eagerly anticipated launch in the US market. Nidra™, a revolutionary new device, stands as the first and only approved treatment for drug-refractory Restless Legs Syndrome (RLS), a chronic condition that has debilitating impacts on sleep and quality of life of millions of adults worldwide.

资金的注入将推动Nidra的进步™强直性运动激活（TOMAC）疗法有望在美国市场推出。奈德拉™, 这是一种革命性的新设备，是第一个也是唯一一个被批准用于治疗药物难治性不宁腿综合征（RLS）的治疗方法，RLS是一种慢性病，对全球数百万成年人的睡眠和生活质量产生衰弱影响。

.

.

Continue Reading

继续阅读

Nidra TOMAC therapy

Nidra-TOMAC疗法

The Nidra™ Tonic Motor Activation therapy is a clinically validated treatment indicated for reducing the symptoms of RLS and improving sleep quality in adults refractory to medications and was granted a De Novo authorization by the US Food and Drug Administration (FDA) in April 2023 after receiving a Breakthrough Device Designation from the agency in 2020..

奈德拉™强直性运动激活疗法是一种经过临床验证的治疗方法，用于减轻RLS症状并改善药物难治性成年人的睡眠质量，并于2020年获得美国食品和药物管理局（FDA）的突破性设备指定后，于2023年4月获得美国食品和药物管理局（FDA）的从头授权。。

Noctrix Health Founder and CEO, Shri Raghunathan, expressed his excitement at the successful funding round, stating, 'We are thrilled to welcome Sectoral Asset Management and other new investors to this esteemed group of partners. This significant milestone, coupled with unwavering support from our existing investors, reflects our shared commitment to establishing a new standard of care for RLS.

Noctrix Health创始人兼首席执行官Shri Raghunathan对融资回合的成功表示兴奋，他说：“我们很高兴欢迎部门资产管理和其他新投资者加入这一备受尊敬的合作伙伴群体。这一重要里程碑，加上我们现有投资者的坚定支持，反映了我们共同致力于为RLS建立新的护理标准。

I extend my gratitude to our dedicated team for their hard work and am humbled by the overwhelming support received.'.

我感谢我们敬业的团队的辛勤工作，并为获得的压倒性支持而感到谦卑。”。

Michael Sjöström, co-founder, and Partner at Sectoral Asset Management, shared his enthusiasm, stating, 'I am honored to join Noctrix Health on its journey in redefining RLS treatment. We believe in the transformative potential of TOMAC therapy and look forward to contributing to the company's continued success.''The strength of Noctrix Health's clinical data combined with the tremendous unmet need underscore the importance of bringing TOMAC therapy to patients with RLS,' said Evan Caplan, Principal at OrbiMed.

部门资产管理公司联合创始人兼合伙人迈克尔·施特伦（MichaelSjöström）也表达了他的热情，他说：“我很荣幸加入Noctrix Health重新定义RLS治疗的旅程。我们相信TOMAC疗法的变革潜力，并期待为公司的持续成功做出贡献。”OrbiMed的负责人埃文·卡普兰（EvanCaplan）说，Noctrix Health的临床数据优势以及巨大的未满足需求突显了为RLS患者提供TOMAC治疗的重要性。

'We have seen how well the team has executed and are excited to continue partnering with them as the company initiates commercialization.''Treo Ventures is thrilled to continue supporting Noctrix Health. This significant financing will allow the company to reach millions of patients with RLS. TOMAC therapy is a patient-friendly, highly effective, non-pharmacologic innovation for patients unhappy with current solutions who need better treatment options,' commented Tracy Pappas, General Partner, Treo Ventures.Noctrix Health has experienced a banner year in 2023, marked by the FDA marketing authorization of TOMAC therapy, followed by several key publications including a recent study demonstrating TOMAC therapy's efficacy in reducing opioid use in patients with RLS, further reinforcing its potential impact on patient outcomes.About Nidra™ TOMAC TherapyThe Nidra™ Tonic Motor Activation (TOMAC) system is the first and only non-pharmacologic, wearable treatment intended to reduce symptoms of primary moderate-severe Restless Legs Syndrome (RLS) and improve sleep quality in adults refractory to medications.

“我们已经看到了团队的表现，并很高兴在公司开始商业化时继续与他们合作。”Treo Ventures很高兴继续支持Noctrix Health。这一重大融资将使该公司能够接触数百万RLS患者。Treo Ventures的普通合伙人特蕾西·帕帕斯（TracyPappas）评论说，对于那些对当前解决方案不满意的患者来说，TOMAC疗法是一种对患者友好、高效、非药物的创新。Noctrix Health在2023年经历了辉煌的一年，其标志是FDA批准了TOMAC疗法的上市，随后发表了几篇关键出版物，包括最近的一项研究，证明了TOMAC疗法在减少RLS患者阿片类药物使用方面的功效，进一步加强了其对患者结局的潜在影响。关于Nidra™托马克治疗Nidra™强直性运动激活（TOMAC）系统是第一个也是唯一一个非药物的可穿戴治疗方法，旨在减轻原发性中重度不宁腿综合征（RLS）的症状，并改善药物难治性成年人的睡眠质量。

It is available in the US by prescription only. For more information on availability or clinical and important safety information, please visit www.nidrarls.com.About .

它在美国只能通过处方获得。有关可用性或临床和重要安全信息的更多信息，请访问www.nidrarls.com.About。